HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Senior Staff Has Final Say Over Disputes In Enzi/Kennedy Bill

This article was originally published in The Tan Sheet

Executive Summary

Senior FDA officials will have final say over drug safety disputes under proposed legislation from Sens. Michael Enzi (R-Wyo.) and Edward Kennedy (D-Mass.)

You may also be interested in...

FDA Safety Plan Is Only First Step, But Agency Says No New Authority Needed

FDA's description of its plan to improve oversight of drug safety acknowledges the agency's efforts are part of an ongoing process - but not necessarily one needing outside involvement

Cleveland Clinic’s Nissen Asks HELP Panel For Stronger Supplement Regulation

Pending legislation on adverse event reporting does not go far enough in expanding regulatory oversight of dietary supplements, the American College of Cardiology president told a Senate committee Nov. 16

GAO Drug Safety Report Recommends Giving Teeth To FDA Postmarket Review

A Government Accountability Office report on drug safety recommends giving FDA the power to mandate postmarketing drug studies

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts